A case series showed that chimeric antigen receptor T-cell therapy targeting CD19 halted the progression of fibrotic organ ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...

Researchers uncover how the skin autonomously produces antibodies through specialized immune structures, maintaining ...

A news feature on the research paper “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition” ...

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...

In the real world, treating relapsed/refractory large B-cell lymphoma with epcoritamab and glofitamab leads to poorer ...

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with ...

A research team led by Prof. Wang Haoyi from the Institute of Zoology (IOZ) of the Chinese Academy of Sciences has developed ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...